Cardiometabolic Health Congress (CMHC)
Avatar

CVOT Data in Your Clinical Practice: Patient Case and Audience Q&A

By Cardiometabolic Health Congress (CMHC) FEATURING Robert Eckel
By Cardiometabolic Health Congress (CMHC) FEATURING Robert Eckel
29 views
October 22, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

18:06
Lilly Obesity

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus

Related Content

AUTOPLAY
64:45
Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

Primer on Diabetes Management

Feat. S. Inzucchi
12:04
Stephen Kopecky

Role of PCSK9 Inhibitors in Diabetes

11:37
ACC 2022 Conference Coverage

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

Feat. P. Heidenreich
28:13
National Lipid Association

New Insights into Triglyceride Therapy and the Role of Omega-3 Fatty…

Feat. R. Mason
11:25
ACC 2023 Conference Coverage

ACC 2023: SGLT2i Use - Dos and Don'ts

Feat. A. Armbruster
31:46
ACC 2024 Insights

ACC 2024 Insights: Evolving Pharmacology for HFrEF vs. HFpFF - With …

Feat. M. Costanzo
59:01
The North American Thrombosis Forum (NATF)

Recent Cholesterol Guidelines and Integration into Clinical Practice

Feat. J. Plutzky, L. Braun, J. Ross
18:43
ASPC 2019 Congress on CVD Prevention

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

Feat. R. DeFronzo
18:43
Canadian Collaborative Research Network

Lp(a): When to Measure it and What to Do About it

Feat. M. O'Donoghue
08:44
AHA 2022 Conference Coverage

AHA 2022: Cardiovascular Benefit of Lowering LDL Cholesterol Below 4…

Feat. N. Marston
21:27
Scripps Health

Lipids Update: Current Guidelines for Lipid Management

Feat. S. R. Mehta
14:50
AHA 2022 Conference Coverage

AHA 2022: Long-Term Efficacy and Safety of Inclisiran in Patients Wi…

Feat. K. Ray
15:06
Robert Busch

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

26:01
Cardiology Fiesta 2017

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Feat. R. DeFronzo
12:26
Juan Frias

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

45:45
Houston Methodist DeBakey Heart and Vascular Center

Directions of Cardiology in the Next Decade: 2022-2032

Feat. E. Braunwald
15:33
Ken Fujioka

Could GLP-1's be a 'Game Changer' For Weight Loss? Ca…

17:44
Rita Jermyn

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

27:24
Cardiometabolic Health Congress (CMHC)

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Feat. L. Sloan
20:24
Diana Isaacs

Tirzepatide for Type 2 Diabetes